Aquestive Therapeutics, Inc. (AQST)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.5700 |
| Open | 2.6000 |
| Bid | 2.5200 x 1800 |
| Ask | 2.6400 x 3100 |
| Day's Range | 2.4800 - 2.6400 |
| 52 Week Range | 2.4800 - 6.9970 |
| Volume | |
| Avg. Volume | 773,244 |
| Market Cap | 102.017M |
| Beta (5Y Monthly) | 3.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7010 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- GlobeNewswire
Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
WARREN, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th. The Aquestive team is scheduled to a hold a presentation that will be available on demand from January
- Motley Fool
Why Aquestive Therapeutics Dived by 29% Today
Aquestive Therapeutics (NASDAQ: AQST) was one of the steeper decliners among biotech stocks Tuesday. The company's shares plummeted more than 29% on a rather discouraging piece of news about one of its top drug candidates. Late Monday night, Aquestive disclosed that it had received notification from the Food and Drug Administration (FDA) regarding its Libervant Buccal Film pipeline drug.
- MarketWatch
Aquestive stock falls as FDA delays decision on experimental seizure treatment
Shares of Aquestive Therapeutics Inc. tumbled 28.4% in premarket trading after the company said Monday that the Food and Drug Administration is delaying the review of its still-investigational seizure treatment. The regulator was expected to announce its decision about whether to approve the therapy by Dec. 23; the FDA said in the notice that it is "currently unable to provide an estimate of the timing of an expected action." The FDA is not requiring any additional information from Aquestive at
